GT Biopharma Stock Market Outlook

Stocks . USA . 
Stock . GT Biopharma
GTBP Stock  USD 0.38  -0.01  -2.56%   
Changes in the tone and volume of recent news coverage can help explain how the market is framing the stock, even when the recommendation label does not change. Around 54% of recent sentiment around GT Biopharma has been mildly defensive over the recent sample. Taken on its own, that leaves Current sentiment reading for GT Biopharma close to neutral right now.
Investor Comfort Level
PanicConfidence
46 · Impartial

Elasticity to Hype and News Sentiment

GT Biopharma news coverage registers positive at 72%, a data point that gauges whether public narrative is leading or lagging the business reality. Cross-checking that reading with earnings momentum and price action helps confirm whether the narrative is running ahead of or behind the business.
Given a 90-day horizon, with an above-average risk tolerance, the model output for GT Biopharma is 'Strong Sell'. The GT Biopharma buy-or-sell recommendation is derived from the selected investment horizon and risk tolerance parameters for GT Biopharma.
  

Run GT Biopharma Outlook Model

The GTBP signal is designed to work alongside the professional consensus covering GT Biopharma. Macroaxis is editorially and financially independent with no stake in GT Biopharma. GT Biopharma's outlook reflects a systematic evaluation of price behavior and fundamental quality.

How This Model Works

The recommendation output for GT Biopharma is a model-based view that converts the selected horizon and risk profile into a standardized reading of the current evidence.

  • Inputs - valuation signals, price behavior, volatility, liquidity, sentiment, and analyst coverage when available
  • Current setup - Three Months with a risk setting described as I am an educated risk taker
  • Limits - the model does not account for taxes, outside holdings, concentration constraints, or investor-specific mandates

Use the output as structured decision support and pair it with your own research, portfolio context, and any professional advice you rely on.

Time Horizon

Risk Tolerance

Update Outlook
SellBuy
Strong Sell

Market Performance

WeakDetails

Volatility

ExtremeDetails

Current Valuation

Below Model EstimateDetails

Odds Of Distress

HighDetails

Economic Sensitivity

Shows low sensitivity to market movementsDetails

Investor Sentiment

ImpartialDetails

Analyst Consensus

BuyDetails

Financial Strenth (F Score)

HealthyDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails
GT Biopharma's current outlook reflects a cautious setup, where weak recent performance and soft fundamental readings cloud near-term visibility. The model's 'Strong Sell' signal reflects persistent headwinds that outweigh the offsetting factors in the model. For the selected horizon, GT Biopharma yields Mean Deviation of 3.86, Standard Deviation of 5.46, and Variance of 29.85, which weigh on the current risk-reward outlook.
This quantitative reading for GT Biopharma is derived from a multi-factor model that evaluates current market conditions, fundamental quality, and momentum alongside the analyst consensus. For additional context on this micro-cap stock in the Health Care sector, examine the full set of GT Biopharma reported fundamentals, including the relationship between the net income ttm and price to earnings to growth. As GT Biopharma appears to be a penny stock, its price to book ttm numbers are an important reference point for this model output.

Recent Events and Market Context

The events below reflect recent headlines associated with GT Biopharma. Not all items directly affect the outlook — they are included to show the broader information environment that can shape sentiment and trading behavior.

Current Analysts Advice

Analyst consensus on GT Biopharma within the Health Care sector is built by aggregating published recommendations from professional researchers into a standardized market view. Current analyst coverage includes about 1 reporting opinions.
Consensus estimates and target prices for GT Biopharma reflect individual analyst assessments and are independent of Macroaxis buy-or-sell guidance. With a current consensus of Buy across 1 analysts, investors usually get the most value by reading this alongside volatility, valuation, and earnings-revision trends.

Returns Distribution Density

The chart below shows the full range of GT Biopharma's daily returns. The chart shows the most common daily returns and how far outliers have reached. Value At Risk measures downside risk while Upside Potential measures the gain side.
Mean Return
-0.29
Value At Risk
-9.68
Potential Upside
9.68
Standard Deviation
5.46
   Return Density   
       Distribution  
Big price swings are rare but central to GT Biopharma risk assessment. The return distribution chart answers that question at a glance. It quantifies the risk-reward profile of different risk-return profiles.

Top Institutional Investors

Revenue scale should be reviewed against peers and reporting history. How GT Biopharma's institutional base reacts to earnings changes can move the stock in the short term. The business currently sits in the Health Care sector and the Pharmaceuticals, Biotechnology & Life Sciences industry. With moderate institutional presence, retail activity has more room to move the price day to day.
Shares
Am Investment Strategies Llc2025-12-31
15 K
Hpm Partners Llc2025-12-31
15 K
Verdence Capital Advisors Llc2025-12-31
13 K
Two Sigma Securities, Llc2025-12-31
12.5 K
Prospera Financial Services Inc2026-03-31
12 K
Hrt Financial Llc2025-12-31
11.8 K
Parsons Capital Management Inc2026-03-31
10.9 K
Bank Of Montreal2025-12-31
10.8 K
Bmo Capital Markets Corp.2025-12-31
10.8 K
Citadel Advisors Llc2025-12-31
80.8 K
Scientech Research Llc2025-12-31
54.7 K
At 13.87 million market cap, GT Biopharma smaller-cap scale means institutional moves shape liquidity but do not guarantee above-market returns. The business currently sits in the Healthcare sector and the Biotechnology industry. Reading GT Biopharma holder concentration alongside float turnover and volatility adds the best context for understanding how smaller-cap ownership shapes price.

Cash Flow Accounts

20222023202420252026 (projected)
Total Cashflows From Investing Activities12.1M-2.0M12.9M11.6M12.2M
Other Cashflows From Investing Activities-12.1M-2.0M12.9M11.6M12.2M
Backtest GT Biopharma

Key Drivers of Volatility and Market Exposure

Risk for GT Biopharma can be divided into market-wide and asset-specific components. While diversification may mitigate unsystematic factors, systematic risk tied to the stock market cannot be eliminated. Historical beta and volatility measures provide context. GT Biopharma's financial profile includes a Mean Deviation of 3.86 and a Standard Deviation of 5.46.
α
Alpha over Dow Jones		-0.2984
β
Beta against Dow Jones-0.4497
σ
Overall volatility		5.34
Ir
Information ratio -0.0541
GT Biopharma has demonstrated noticeable return variability, with semi-deviation around 0.0%. This metric focuses on negative return swings and helps describe downside sensitivity. With a beta of -0.4497, GT Biopharma has historically been less reactive to market-wide shifts. GT Biopharma Sharpe ratio stands at -0.0431, signaling that volatility has not been rewarded with positive excess returns.

Fundamentals Vs Peers

Peer-level comparison for GT Biopharma tests whether the market's pricing reflects relative fundamental strength or weakness. When GT Biopharma's ratios diverge materially from peers, the gap signals either a mispricing opportunity or a structural difference worth investigating. The peer context below makes GT Biopharma's fundamental positioning more precise than standalone analysis allows.
    
 Better Than Average     
    
 Worse Than Average Compare GT Biopharma to competition
FundamentalsGT BiopharmaPeer Average
Return On Equity TTM-13.77-0.31
Return On Asset TTM-1.26-0.14
Current Valuation4.56 M16.62 billion
Shares Outstanding35.62 M571.82 million
Shares Owned By Insiders3.90 %10.09 %
Shares Owned By Institutions4.60 %39.21 %
Number Of Shares Shorted671.07 K4.71 million
Price To Book TTM2.48 X9.51 X
Price To Sales TTM204.96 X11.42 X
EBITDA TTM-34.32 M3.9 billion
Net Income TTM-28.35 M570.98 million
Cash And Equivalents TTM23.73 M2.7 billion
Cash Per Share TTM0.76 X5.01 X
Total Debt TTM2.32 M5.32 billion
Debt To Equity TTM0.01 %48.70 %
Current Ratio TTM2.78 X2.16 X
Book Value Per Share TTM0.23 X1,931
Cash Flow From Operations TTM-12.91 M971.22 million
Short Ratio TTM1.11 X4.00 X
Earnings Per Share-6.68 X3.12 X
Price To Earnings To Growth1.05 X4.89 X
Target Price3.0N/A
Number Of Employees118,840
Trailing Beta0.64-0.15
Market Capitalization TTM13.87 M19.03 billion
Total Asset TTM8.11 M29.47 billion
Retained Earnings TTM-723.9 M9.33 billion
Working Capital TTM5.79 M1.48 billion
Net Asset8.11 MN/A
Note: Acquisition by Michael Breen of 50000 shares of GT Biopharma at 0.5 subject to Rule 16 b-3 [view details]

Market Momentum

With RSI at 47 and beta at -0.4497, GT Biopharma strength signals show whether demand and trading pressure are supporting or weakening the current setup. That inverse market relationship means conventional momentum frameworks need adjustment.
Accumulation Distribution24997.13
Daily Balance Of Power-0.50
Rate Of Daily Change0.97
Day Median Price0.38
Day Typical Price0.38
Price Action Indicator-0.01
Period Momentum Indicator-0.01
Relative Strength Index47.92

Recommendation Framework, Assumptions & Editorial Oversight

The model output for GT Biopharma reflects the current horizon and risk settings, refreshes as underlying data changes, and is intended to organize evidence rather than replace investor judgment. Current model inputs for GT Biopharma include ROE of -13.77%, market cap of 13.87 million. External analyst coverage is currently summarized as Buy across 1 analyst, but it is treated here as a secondary reference input rather than a stand-alone recommendation. Published target-price assumptions may also be reviewed when available, but they can change quickly as analyst models are revised.

GT Biopharma analytics rely on periodic company reporting and market reference feeds, with quality checks and normalization applied. The model combines valuation, price behavior, volatility, and sentiment into a standardized quantitative view.

Editorial Review & Methodology Oversight

Vlad Skutelnik
Role: Macroaxis Contributor
Finance background: Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
Oversight scope: Reviews recommendation-framework framing, source assumptions, and disclosure language.
Last reviewed on May 7th, 2026

Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.